- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- 【Updated on June 30, 2025】Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
A Japanese Case of Familial Hypercholesterolemia with a Protein-truncating Variant in LDLR and a PCSK9 Variant without Significant Atherosclerosis but Showing Remarkable Achilles Tendon Thickening
-
- Minamizuka Takuya
- Graduate School of Medicine, Chiba University Endocrine Metabolism/Hematology/Geriatric Medicine, Japan
-
- Kobayashi Junji
- Graduate School of Medicine, Chiba University Endocrine Metabolism/Hematology/Geriatric Medicine, Japan
-
- Tada Hayato
- Graduate School of Medicine, Kanazawa University Cardiovascular Medicine, Japan
-
- Koshizaka Masaya
- Graduate School of Medicine, Chiba University Endocrine Metabolism/Hematology/Geriatric Medicine, Japan
-
- Maezawa Yoshiro
- Graduate School of Medicine, Chiba University Endocrine Metabolism/Hematology/Geriatric Medicine, Japan
-
- Ono Hiraku
- Graduate School of Medicine, Chiba University Endocrine Metabolism/Hematology/Geriatric Medicine, Japan
-
- Yokote Koutaro
- Graduate School of Medicine, Chiba University Endocrine Metabolism/Hematology/Geriatric Medicine, Japan
Search this article
Description
<p>The patient was a 54-year-old woman with familial hypercholesterolemia and remarkable Achilles tendon thickening. At 20 years old, the patient had a total cholesterol level of approximately 300 mg/dL. She started receiving rosuvastatin (5 mg/day) for low-density lipoprotein cholesterol (LDL-C) 235 mg/dL at 42 years old, which was increased to 10 mg/day at 54 years old, decreasing her serum LDL-C level to approximately 90 mg/dL. The serum Lp (a) level was 9 mg/dL. A computed tomography coronary angiogram showed no significant stenosis. Next-generation sequencing revealed a frameshift variant in LDL receptor (LDLR) (heterozygous) and a missense variant in proprotein convertase subtilisin/kaxin type 9 (PCSK9) (heterozygous). Continued statin therapy, in addition to low Lp (a) and female sex, can help prevent cardiovascular disease. </p>
Journal
-
- Internal Medicine
-
Internal Medicine 63 (15), 2137-2142, 2024-08-01
The Japanese Society of Internal Medicine